2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, The Lancet, vol.369, issue.9555, pp.29-36, 2007. ,
DOI : 10.1016/S0140-6736(07)60028-2
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer, New England Journal of Medicine, vol.354, issue.8, pp.809-820, 2006. ,
DOI : 10.1056/NEJMoa053028
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2, Nature Clinical Practice Oncology, vol.24, issue.9, pp.531-542, 2008. ,
DOI : 10.1038/bjc.1992.22
-Overexpressing Metastatic Breast Cancer, Journal of Clinical Oncology, vol.20, issue.3, pp.719-726, 2002. ,
DOI : 10.1200/JCO.2002.20.3.719
The 17q12-q21 amplicon: Her2 and topoisomerase-II?? and their importance to the biology of solid tumours, Cancer Treatment Reviews, vol.33, issue.1, pp.64-77, 2007. ,
DOI : 10.1016/j.ctrv.2006.10.001
ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction, Clinical Cancer Research, vol.16, issue.8, pp.2391-2401, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-2471
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer, Breast Cancer Research and Treatment, vol.224, issue.2, pp.181-189, 2007. ,
DOI : 10.1016/j.canlet.2004.11.007
HER-2 amplification and topoisomerase II? gene aberrations as predictive markers in nodepositive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil, Clin Cancer Res, vol.8, pp.1107-1116, 2002. ,
Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group, Journal of Clinical Oncology, vol.23, issue.30, pp.7483-7490, 2005. ,
DOI : 10.1200/JCO.2005.11.007
???Amplified Breast Cancer: Scandinavian Breast Group Trial 9401, Journal of Clinical Oncology, vol.24, issue.16, pp.2428-2436, 2006. ,
DOI : 10.1200/JCO.2005.02.9264
Amplification and overexpression of topoisomerase II? predict response to anthracycline-based therapy in locally advanced breast cancer, Clin Cancer Res, vol.8, pp.1061-1067, 2002. ,
Topoisomerase II-?? (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy, European Journal of Cancer, vol.39, issue.5, pp.631-634, 2003. ,
DOI : 10.1016/S0959-8049(02)00745-1
, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients, Journal of Clinical Oncology, vol.28, issue.6, pp.984-990, 2010. ,
DOI : 10.1200/JCO.2009.24.1166
Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy, JNCI Journal of the National Cancer Institute, vol.86, issue.3, pp.644-650, 2009. ,
DOI : 10.1023/B:BREA.0000036783.88387.47
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer, Acta Oncologica, vol.39, issue.9, pp.590-596, 2006. ,
DOI : 10.1016/S0959-8049(03)00265-X
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-?? gene amplification and protein overexpression in locally advanced/metastatic breast cancer, International Journal of Oncology, vol.24, pp.201-209, 2004. ,
DOI : 10.3892/ijo.24.1.201
Amplification and Deletion of Topoisomerase II?? Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer, The American Journal of Pathology, vol.156, issue.3, pp.839-847, 2000. ,
DOI : 10.1016/S0002-9440(10)64952-8
Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer, Breast Cancer Research and Treatment, vol.27, issue.26, pp.481-489, 2010. ,
DOI : 10.1016/S0002-9440(10)64952-8
, Topoisomerase II? amplification does not predict benefit from
13:R15 http://breast-cancer-research.com/content/13/1/R15 dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013, Breast Cancer Research J Clin Oncol, vol.27, pp.3430-3436, 2009. ,
Status, Journal of Clinical Oncology, vol.27, issue.24, pp.3881-3886, 2009. ,
DOI : 10.1200/JCO.2008.20.1566
HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy, Journal of Clinical Oncology, vol.26, issue.5, pp.736-744, 2008. ,
DOI : 10.1200/JCO.2007.15.4716
Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers, JNCI Journal of the National Cancer Institute, vol.12, issue.8, pp.615-618, 2009. ,
DOI : 10.1023/A:1011669223035
URL : https://academic.oup.com/jnci/article-pdf/101/9/615/7671610/djp092.pdf
Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer, The American Journal of Pathology, vol.163, issue.5, pp.1979-1984, 2003. ,
DOI : 10.1016/S0002-9440(10)63556-0
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines, Laboratory Investigation, vol.115, issue.5, pp.491-503, 2008. ,
DOI : 10.1042/BJ20050378
Comprehensive copy number profiles of breast cancer cell model genomes, Breast Cancer Research, vol.16, issue.1???2, p.9, 2006. ,
DOI : 10.1093/emboj/16.7.1647
URL : https://breast-cancer-research.biomedcentral.com/track/pdf/10.1186/bcr1370?site=breast-cancer-research.biomedcentral.com
Genomic and Expression Profiling of Chromosome 17 in Breast Cancer Reveals Complex Patterns of Alterations and Novel Candidate Genes, Cancer Research, vol.64, issue.18, pp.6453-6460, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-0756
URL : https://hal.archives-ouvertes.fr/inserm-00157287
the pursuit of targeted therapy in breast cancer, Cancer Treat Rev, vol.36, pp.17-29, 2010. ,
Reliability and Discriminant Validity of HER2 Gene Quantification and Chromosome 17 Aneusomy Analysis by Real-Time PCR in Primary Breast Cancer, The International Journal of Biological Markers, vol.61, issue.1, pp.20-29, 2006. ,
DOI : 10.1038/modpathol.3880505
URL : https://hal.archives-ouvertes.fr/hal-01823855
Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories, Journal of Clinical Oncology, vol.28, issue.28, pp.4300-4306, 2010. ,
DOI : 10.1200/JCO.2009.24.8211
Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens, Gynecologic Oncology, vol.116, issue.2, pp.234-239, 2010. ,
DOI : 10.1016/j.ygyno.2009.10.067
Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17, Cancer, vol.16, issue.suppl 24, pp.48-53, 2011. ,
DOI : 10.1097/PDM.0b013e318064c72a
Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase II? genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization, Arch Pathol Lab Med, vol.129, pp.39-46, 2005. ,
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistry, Breast Cancer Research, vol.121, issue.2, pp.267-273, 2005. ,
DOI : 10.1309/FUQH92B039025LHG
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601), The Lancet Oncology, vol.11, issue.3, pp.266-274, 2010. ,
DOI : 10.1016/S1470-2045(10)70006-1
Amplification of HER2 is a marker for global genomic instability, BMC Cancer, vol.10, issue.1, p.297, 2008. ,
DOI : 10.1093/hmg/10.7.705
URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-8-297?site=bmccancer.biomedcentral.com
genes in breast cancer, Molecular Oncology, vol.25, issue.1, pp.161-168, 2010. ,
DOI : 10.1200/JCO.2006.09.2775
MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain, International Journal of Oncology, vol.22, pp.1369-1374, 2003. ,
DOI : 10.3892/ijo.22.6.1369
The landscape of somatic copy-number alteration across human cancers, Nature, vol.21, issue.7283, pp.899-905, 2010. ,
DOI : 10.4161/cc.6.6.4035
URL : http://europepmc.org/articles/pmc2826709?pdf=render
Alternative mechanisms of gene amplification in human cancers, Genes, Chromosomes and Cancer, vol.2, issue.2, pp.125-132, 2004. ,
DOI : 10.1038/19560
Genomic instability in breast cancer: Pathogenesis and clinical implications, Molecular Oncology, vol.276, issue.3, pp.255-266, 2010. ,
DOI : 10.1016/0165-1110(92)90009-X
URL : https://febs.onlinelibrary.wiley.com/doi/pdf/10.1016/j.molonc.2010.04.001
Gene amplification in cancer, Trends in Genetics, vol.22, issue.8, pp.447-455, 2006. ,
DOI : 10.1016/j.tig.2006.06.007
Final results of a meta-analysis testing HER2 and topoisomerase II? genes as predictors of incremental benefit from anthracyclines in breast cancer [abstract], J Clin Oncol, issue.15, p.28519, 2010. ,
Topoisomerase II alpha as a marker predicting anthracyclines??? activity in early breast cancer patients: Ready for the primetime?, European Journal of Cancer, vol.44, issue.18, pp.2791-2798, 2008. ,
DOI : 10.1016/j.ejca.2008.09.014
Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy, J Clin Oncol, 2010. ,
Isolation and Characterization of PBP, a Protein That Interacts with Peroxisome Proliferator-activated Receptor, Journal of Biological Chemistry, vol.9, issue.41, pp.25500-25506, 1997. ,
DOI : 10.1038/42972
URL : http://www.jbc.org/content/272/41/25500.full.pdf
Differential Recruitment of the Mammalian Mediator Subunit TRAP220 by Estrogen Receptors ER?? and ER??, Journal of Biological Chemistry, vol.19, issue.26, pp.23397-23404, 2001. ,
DOI : 10.1073/pnas.96.7.3999
Vitamin D-interacting Protein 205 (DRIP205) Coactivation of Estrogen Receptor ?? (ER??) Involves Multiple Domains of Both Proteins, Journal of Biological Chemistry, vol.1, issue.51, pp.53602-53612, 2004. ,
DOI : 10.1210/me.2002-0351
High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer, Breast Cancer Research, vol.10, issue.3, p.25, 2010. ,
DOI : 10.1186/bcr2124
Characterization of topoisomerase II? gene amplification and deletion in breast cancer, Genes, Chromosomes and Cancer, vol.79, issue.2, pp.142-150, 1999. ,
DOI : 10.1038/bjc.1996.647
Does Polysomy of Chromosome 17 Have a Role in ERBB2 and Topoisomerase IIα Expression?, Tumor Biology, vol.7, issue.4, pp.221-228, 2007. ,
DOI : 10.1002/gcc.20008
Topoisomerase II?? Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out, Journal of Clinical Oncology, vol.27, issue.21, pp.3416-3417, 2009. ,
DOI : 10.1200/JCO.2009.22.6449
erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer, JNCI: Journal of the National Cancer Institute, vol.244, issue.3, pp.1361-1370, 1998. ,
DOI : 10.1126/science.2470152
URL : https://academic.oup.com/jnci/article-pdf/90/18/1361/18048223/90-18-1361.pdf
and Responsiveness of Breast Cancer to Adjuvant Chemotherapy, New England Journal of Medicine, vol.354, issue.20, pp.2103-2111, 2006. ,
DOI : 10.1056/NEJMoa054504
status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials, J Natl Cancer Inst, vol.100, pp.214-234, 2008. ,
, NCBI Sequence Viewer version 2.10
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers, Breast Cancer Research, vol.100, issue.15 Suppl, pp.10-1186, 2011. ,
DOI : 10.1093/jnci/djm252
URL : https://hal.archives-ouvertes.fr/hal-01825781
13:R15 http://breast-cancer-research.com/content, Breast Cancer Research, vol.131, p.15, 2011. ,